Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|March 26, 2025
Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the USDivyan Chopra, David M Waterhouse, Ihtisham Sultan, et al.
Clinical Lung Cancer|February 9, 2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II studyDavid R Spigel, David M Waterhouse, Steve Lane, et al.
Clinical Lung Cancer|June 30, 2021
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community OncologistsDavid M Waterhouse, Wan-Yu Tseng, Janet L Espirito, et al.
Oncotargets and Therapy|December 2, 2021
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion DiagnosticsMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Respiratory Medicine and Research|August 14, 2025
Real-world treatment patterns, healthcare resource utilization, and healthcare costs in patients in the United States with metastatic non-small cell cancer receiving second or subsequent line systemic anticancer therapyDivyan Chopra, Ihtisham Sultan, David M Waterhouse, et al.
JCO Oncology Practice|June 27, 2023
Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based PracticeMolly A Mendenhall, Andrew Guinigundo, Dan Davies, et al.
JCO Oncology Practice|September 22, 2023
Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven ChangeDavid M Waterhouse, Patrick Ward, David R Drosick, et al.
Advances in Therapy|October 29, 2024
Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving SotorasibIhtisham Sultan, David M Waterhouse, Divyan Chopra, et al.
Clinical Genitourinary Cancer|May 21, 2013
High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Dianna L Shipley, James Reeves, et al.
JCO Oncology Practice|May 1, 2023
Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell Lung Cancer in a Large Community Oncology PracticeDavid M Waterhouse, Patrick Ward, Suzzette Arnal, et al.
Pageof 5